Common Errors in the Treatment of IBD: Case Studies Gary R. Lichtenstein, MD David T. Rubin, MD Gary Lichtenstein, MD Disclosures Research, Advisory, and/or Honorarium • Abbott • Alaven • Bristol-Myers Squibb • Elan • Ferring • Hospira • Meda • Luitpold / American Regent • Millenium • Ono • Pfizer • Prometheus • Salix • Santarus • ScheringPlough • Shire • Takeda • UCB • Warner Chilcott Some Common Errors in IBD Management 1. 2. 3. 4. 5. Delay in diagnosis! This is not usually a gastroenterologist’s error. Steroids as initial therapy for mild to moderate UC- trust the evidence! Using anti-TNF therapy as mono therapy- concomitant is favored for most patients at least for induction. Avoiding surgery when it is needed. Under dosing therapies: – 5-ASA – focus on delivery – Thiopurines – understand metabolism and shunters – TNF – in some patients (maybe less than we would like to think) 6. 7. 8. Not vaccinating Ignoring vitamin D Relying on “crisis management” rather than proactive monitoring and control 9. Dismissing patient interests in diet or complementary therapies rather than working with them 10. Not referring to mental health professionals Why Do Patients With IBD Not Respond To Their Medications? Primary Nonresponse Secondary Nonresponse • • • • • • • • Drug/mechanism just doesn’t work Wrong diagnosis – Infection – Ischemia – Crohn’s disease Wrong dose – Not enough – Too much? – pK issues Wrong delivery – Rationale Allergy/intolerance • • Change in dose (by you) Change in delivery Change in physiology – Does disease change over time? Intentional nonadherence – Episodic dosing strategy – Denial – Fear of therapy Unintentional nonadherence – Can’t afford medication – Inconvenient dosing regimen Patient Case 1 Diagnostic Evaluation • Female, age 23 yr; well until 5 mo ago • Symptoms – Pain – Diarrhea (4–6 loose stools/day) – 5-lb weight loss • Physical examination – Tender RLQ – No mass • Social History – Cigs: 1ppd x 5 yrs CRP = C-reactive protein; RLQ = right lower quadrant. • Laboratory values – – – – WBC: 4,500 cells/µL Hgb: 10.5 g/dL CRP: 5.5 mg/dL Albumin: 3.5 g/dL • Colonoscopy – Terminal ileum and cecum with numerous aphthous ulcerations – Biopsies c/w Crohn’s • SBFT – Mild bowel-wall thickening with slight narrowing in terminal ileum only Initial Treatment • Diagnosis – Mild-to-moderate ileocecal CD • Treatment goals – Induce rapid, complete remission – Minimize the potential for side effects • Treatment prescribed – Mesalamine 1.2 g TID • Response – No clinical improvement after 3 weeks Mesalamine is not FDA approved for the treatment of Crohn’s disease in the United States. Induction Nonresponder • What is the most appropriate treatment option in this patient ? 1. Continue mesalamine at a higher dose 2. Change to another 5-ASA derivative 3. Add a systemic corticosteroid –prednisone 40 mg orally daily 4. Switch to EC budesonide at 9 mg a day Treatment Options for Mild Moderate Crohn’s Disease Sequential Therapies for Crohn’s Disease Disease Severity at Presentation Natalizumab Anti-TNF Severe Corticosteroid Anti-TNF+/Thiopurine/MTX Thiopurine/MTX Moderate Aminosalicylate Budesonide Mild Aminosalicylate Budesonide/Thiopurine Induction Maintenance Step-Up according to severity at presentation or failure at prior step Conventional CD Therapy is Sequential Mild Moderate Aminosalicylates Antibiotics Locally Active Oral Corticosteroids Oral Corticosteroids Antimetabolites (AZA,6-MP, MTX) Severe TNF antagonists (IFX, ADA, CZP) Parental Corticosteroids Bowel Rest Natalizumab Surgery Treatment of IBD I. Establish the Correct Diagnosis, Severity of Disease & Extent of Disease Ulcerative Colitis versus Crohn’s Disease Disease Distribution Severity of Disease ACG Guidelines Determining Severity of Crohn’s Disease Mild to Moderate Ambulatory without toxicity, no abdominal tenderness, painful mass, or obstruction Moderate to Severe Unresponsive to treatment for mild-to-moderate stage or with prominent fever, weight loss, anemia, abdominal pain and tenderness, or intermittent nausea or vomiting Severe to Fulminant Persistent symptoms on corticosteroids or with high fever, rebound tenderness, cachexia, or abscess Asymptomatic, no inflammatory sequelae, responsive to medication or surgery, or not Remission requiring systemic corticosteroids Lichtenstein GR, Hanauer SB, Sandborn WJ. Am J Gastroenterol . 2009; 104(2):465-83 . Mesalamine Delivery Systems Sulfasalazine Olsalazine COOH (Azulfidine) (Dipentum) NHSO2 N N N=N 5-ASA CH 5-ASA N=N 5-ASA Sulfapyridine Mesalamine Mesalamine Mesalamine Controlled-release Capsules Delayed-release Capsules (Pentasa) (Asacol) Rectal suspension enema / suppository Gastro-resistant/pH (Rowasa, Canasa) (Lialda) Mesalamine Balsalazide Disodium Capsules (Colazal) 5-ASA 5-ASA 5-ASA 5-ASA Ethylcellulose Microspheres Eudragit S/L Mesalamine Granulated formulation (Apriso) NaOOC MMX technology 5-ASA (ABA) inert carrier OH NCCDS: Response to Therapy for Active Crohn’s Disease 70 60 50 Sulfasalazine 1 g/15 kg (5 g) Patients 40 (%) 30 13% 20 Placebo 10 0 0 5 10 15 Weeks after Randomization NCCDS, National Cooperative Crohn’s Disease Study. Summers RW et al. Gastroenterology 1979;77:847-869 Meta-Analysis: Mesalamine in Active Crohn’s Disease Change from baseline in CDAI score Pentasa® 4 g Pentasa® 4 g minus Placebo Placebo 0 0 -10 -10 P=0.7 -20 P=0.5 -20 -30 P=0.04 -30 -40 -50 -40 P=0.7 -60 -50 -70 -80 P=0.04 P=0.005 -60 P=0.05 Crohn's I Crohn’s II Crohn's III Overall n=155 n=150 n=310 n=615 P=0.005 Crohn's I Crohn's II Crohn's III n=155 Hanauer, Stromberg. Clinical Gastroenterology & Hepatology 2004 n=150 n=310 Overall n=615 Role of Antibiotics in Crohn’s Disease • Widespread use despite insufficient evidence – Inadequate data for metronidazole and ciprofloxacin as first-line therapy • May be useful in the management of – Complications – Perianal disease – Small Intestinal Bacterial Overgrowth – Postoperative prophylaxis • Little, if any, effect on small bowel disease • Potential for resistance and selective overgrowth and Clostridium Difficile infection Corticosteroid Therapy for Crohn’s Disease Immediate Outcome* (n = 74) Complete Remission 58% (n = 43) Partial Remission 26% (n = 19) No Response 16% (n = 12) 1-Year Outcome (n = 74) Prolonged Response 32% (n = 24) Steroid Dependent 28% (n = 21) Surgery 38% (n = 28) *30 days after initiating corticosteroid therapy. Faubion W, et al. Gastroenterology. 2001;121:225-260. Budesonide in Active Ileal/ Right Colonic Crohn’s Disease Budesonide CIR 9 mg Mesalamine* 4 g Prednisolone 40 mg Placebo Patients in Remission (%) 80 70 60 66% 53% 62% 51% 50 36% 40 30 20% 20 10 0 10 Weeks1 8 Weeks2 CIR = controlled ileal release. *Mesalamine controlled-release capsules (Pentasa). 1. Rutgeerts P, et al. N Engl J Med. 1994;331:842-845. 2. Greenberg GR, et al. N Engl J Med. 1994;331:836-841. 3. Thomsen OO, et al. N Engl J Med. 1998;339:370-374. 16 Weeks3 Corticosteroids in Crohn’s disease • Budesonide is first-line therapy for mildmoderate ileal or right colon disease – Maintenance therapy? • Systemic steroids for moderate-severe disease • High risk of steroid-dependence • Greatest risk of long-term side effects – AGA Quality guidance • Attempt steroid weaning • Monitor for osteoporosis Change of Therapy • Treatment – EC budesonide 9 mg QD for 8 weeks • Outcome – Remission attained at 5 weeks – Hgb: 11.2 g/dL – Mild facial acne – EC Budesonide successfully tapered to complete cessation after 8 weeks • Plan – Watchful waiting Followup • Followup – 2 weeks after cessation of EC Budesonide symptomatic recurrence is noted – 6 BM / day with RLQ abdominal pain – Perianal drainage from a small fistula was noted • Labs: – WBC- 13.0 x 109 / L – Hgb: 8.7 g/dL – ESR- 45 mm/hr – CRP - 22 mg/L Recommendations • Which of the following are appropriate at this time 1.) 2.) 3.) 4.) 5.) 6.) MRI enterography CT enterography Stool for C diff Ask patient to stop smoking 1 and 4 1, 3 and 4 Refractory IBD • Establish the Correct Diagnosis, Severity of Disease & Extent of Disease • Evaluate for Disease Complications • Evaluate for Enteric Infections • Use Optimal Medication Doses • Miscellaneous • • • • NonAdherence Paradoxical Responses NSAIDs Cigarettes Disease Complications Abdominal / Pelvic Abscess CT abdomen and pelvis with oral and iv contrast MRI pelvis with gadolinium Mesenteric Venous Thrombosis CT abdomen and pelvis with oral and iv contrast MRI pelvis with gadolinium Enteric Infections Bacterial Infections CMV Clostridium Difficile Parasitic Diseases “Pseudointractibility” of IBD • • • • CMV Clostridium Difficile NSAIDs Cigarette • Cessation in UC • Use in CD MRI Enterography: Active Crohn’s Disease T2 and Post-gad images demonstrating marked thickening and enhancement of TI. Note elevated T2 signal within and adjacent to TI (arrows) indicating active disease. Followup • Followup – Therapy was initiated with infliximab 5 mg /kg at 0,2, and 6 weeks the every 8 weeks and also AZA 2.5 mg/kg was given (TPMT enzyme activity was normal). – Oral Iron was given (Ferritin checked was 10 ng/mL). – Within a period of 3 months symptomatic remission was noted. – Hgb - 11.0 grams – WBC- 9.9 g/dL – ESR- 12 mm/hr – CRP - 3.8 mg/L CASE 2: The Patient Failing Thiopurine Therapy Two Brothers with Ulcerative Colitis • Patient #1: 18 yo with pancolitis, steroid responsive but steroid dependent. – TPMT normal – 6-MP started at 1.5 mg/kg – Unable to wean steroids below 15 mg • Patient #2: 15 yo brother of patient #1, ulcerative proctitis, steroid resistant – TPMT normal – 6-MP started at 1.5 mg/kg – Not responding Metabolism of Azathioprine and 6-Mercaptopurine 6-Methylmercaptopurine TPMT HPRT Azathioprine 6-Mercaptopurine XO 6-Thiouric acid Chan GL et al. J Clin Pharmacol. 1990;30:358. Thioinosinic acid 6-Thioguainine nucleotides Association Between Clinical Response and Both 6-TGN and Intermediate Activity TPMT Genotype in Pediatric Patients With IBD Therapeutic Efficacy 6-TG Quartiles Frequency of 6-TG level >235 (pmol/8 × 108 RBC) (%) 78% 100 80 41% 60 40 20 n=44 n=42 n=43 n=44 0 0–173 174–235 236–367 368–1,203 Dubinsky MC et al. Gastroenterology 2000;118:705. Frequency of 6-TG level Frequency of Response Frequency of response (pmol/8 × 108 RBC) (%) 100 80 65 60 40 27 20 0 Response Failure The Patient not Responding to Thiopurine • Confirm adherence, consider metabolites: 6-TG 6-MMP undetectable undetectable Dubinsky. Curr Gastroenterol Rep. 2003;5(6):506-11. Possible cause Non-adherent or underdosed Recommendation Understand why pt not taking med or increase dose The Patient not Responding to Thiopurine • Confirm adherence, consider metabolites: 6-TG 6-MMP undetectable undetectable Non-adherent or underdosed Understand why pt not taking med or increase dose Low (<230) Low or undetectable Non-adherent or underdosed Discuss adherence, increase dose Dubinsky. Curr Gastroenterol Rep. 2003;5(6):506-11. Possible cause Recommendation The Patient not Responding to Thiopurine • Confirm adherence, consider metabolites: 6-TG 6-MMP undetectable undetectable Non-adherent or underdosed Understand why pt not taking med or increase dose Low (<230) Low or undetectable Non-adherent or underdosed Discuss adherence, increase dose Low (<230) High (>5700) 6-MMP shunter 1. Increase thiopurine, or 2. Consider allopurinol, or 3. Switch agents Dubinsky. Curr Gastroenterol Rep. 2003;5(6):506-11. Possible cause Recommendation The Patient not Responding to Thiopurine • Confirm adherence, consider metabolites: 6-TG 6-MMP undetectable undetectable Non-adherent or underdosed Understand why pt not taking med or increase dose Low (<230) Low or undetectable Non-adherent or underdosed Discuss adherence, increase dose Low (<230) High (>5700) 6-MMP shunter 1. Increase thiopurine, or 2. Consider allopurinol, or 3. Switch agents “Therapeutic” (>230-<400) or High (>400) Normal range or high Primary nonresponder 1. Assess disease 2. Switch to different mechanism Dubinsky. Curr Gastroenterol Rep. 2003;5(6):506-11. Possible cause Recommendation Brothers with Shunting 6-MP monotherapy Pt TPMT 6-TGN 6-MMP ALT 1 23.0 137 13,477 114 2 19.7 301 12,796 141 The Patient not Responding to Thiopurine • Confirm adherence, consider metabolites: 6-TG 6-MMP undetectable undetectable Non-adherent or underdosed Understand why pt not taking med or increase dose Low (<230) Low or undetectable Non-adherent or underdosed Discuss adherence, increase dose Low (<230) High (>5700) 6-MMP shunter 1. Increase thiopurine, or 2. Consider allopurinol, or 3. Switch agents “Therapeutic” (>230-<400) or High (>400) Normal range or high Primary nonresponder 1. Assess disease 2. Switch to different mechanism Dubinsky. Curr Gastroenterol Rep. 2003;5(6):506-11. Possible cause Recommendation Practical Approach to Allopurinol and Thiopurine Combination Therapy • Not for everyone! Be aware of safety concerns. • Choose patient (and MD) wisely: – – – – • • • • • • Active disease Adherence with thiopurines Subtherapeutic 6-TGn, supratherapeutic 6-MMP Elevated LFTs or nausea may be present but not necessary to consider this approach Drop thiopurine to 25 mg (6-MP) or 50 mg (AZA) Allopurinol 100 mg Notify pharmacist! CBC weekly for one month, then monthly… Metabolites at week 3 Dose adjustment if necessary but in small increments Govani and Higgins. J Crohns Colitis 2010;4(4):444-9. Sparrow, et al. J Crohns Colitis 2009;3(3):162-7. Brothers with Shunting 6-MP monotherapy 6-TGN 6-MMP ALT 6-MP/allopurinol Pt TPMT 6-TGN 6-MMP ALT 1 23.0 137 13,477 114 422 -- 21 2 19.7 301 12,796 141 351 -- 25 Both patients responded quickly (within 2-3 weeks), have been in stable steroid-free remission for >2 years. Case 3 • 21 year old male with a 4 year history of extensive small bowel CD treated with infliximab for the past 3 years presents with increasing cramping abdominal pain, 12 pound weight loss and diarrhea • No recent travel or antibiotics • No previous abdominal surgery • SH: Does not smoke • FH: No FH of IBD • On infliximab 10mg/kg q 6 wk Case 3 • PE shows a well appearing male in NAD with fullness in the RLQ • Stool samples for enteric pathogens and C. diff negative • MRE- 5cm segment of small bowel disease with small bowel dilation proximal to the area of involvement but w/o inflammation • IFX level (trough: 9.0 mcg/ml) • ATI negative • LABS: WBC – 8.6 K Hgb – 12 Ptlt- 334 K CRP- 3.3 (Normal < 4 mg/dl) Case 3 Please choose the best management strategy 1. Increase infliximab 2. Add an antimetabolite (AZA/6MP/MTX) and continue infliximab 3. Switch to adalimumab or certolizumab 4. Switch to natalizumab 5. Continue infliximab but evaluate for small bowel intestinal overgrowth, irritable bowel syndrome and consider surgical options 6. Send for ileocecectomy Factors that Influence the PK of TNF Antagonists Impact on TNF antagonist PK Presence of ADAs Decreases drug concentration Increases clearance Worse clinical outcomes Concomitant use of immunosuppressives Reduces ADA formation Increases drug concentration Decreases drug clearance Better clinical outcomes Low serum albumin concentration Increases drug clearance Worse clinical outcome High baseline CRP concentration Increase drug clearance High baseline TNF concentration May decrease drug concentration by increasing clearance High body size May increase drug clearance Sex Males have higher clearance ENT06169 10/07 Ordas I et. al. Clin Gastroenterol Hepatol. 2012; 10:1079-1087. Aim Clinical Outcomes of Patients With Detectable Human Anti-Chimeric Antibodies or Subtherapeutic IFX Concentrations • Examine the utility of measuring HACA and IFX concentrations and compare subsequent clinical management and response Detectable HACA Subtherapeutic concentrations Response to test Complete/partial response (%) P value Increase IFX 1/6 (17) <0.004 Change anti-TNF 11/12 (92) Increase IFX 25/29 (86) Change anti-TNF 2/6 (33) <0.016 HACA and IFX concentration testing impacted treatment decisions in 73% of patients and were a useful adjunct to clinical and endoscopic/radiologic assessment ENT06169 10/07 Afif W, et al. Am J Gastroenterol. 2010; 105:1133-1139. Followup: Case 3 • • • • Therapeutic infliximab trough level (7 μg/mL) and short segment of fixed noninflammatory disease Send to surgery and laparoscopic ileocecectomy performed Treated postop with metronidazole 500mg po bid for 3 months as well as 6MP Doing well 10 months postop with colonoscopy demonstrating 2 isolated aphthous erosions in the neoterminal ileum Drug Levels Predict Immunogenicity: Serum IFX at Week 4 After an Infusion Predicts Eventual Appearance of ATI’s in Episodic Dosing Week 4 serum level and subsequent ATI titre P = ns P<0.001 P<0.001 • “an IFX level of <4 μg/ml measured 4 weeks after the first infusion had a PPV of 81% to detect the development of high ATIs during the later course of treatment” • “an IFX level of >15 μg/ml measured 4 weeks after the first infusion was 80% predictive for the absence of ATIs during later follow-up.” “Therefore, IFX levels measured early after the first infusion of IFX (at 4 weeks) are a good prognostic parameter for development of immunogenicity.” Vermeire et al. Gut 2007;56;1226-1231 Patients With Sustained ATI Associated With LOR Patients who discontinued IFX treatment due to LOR/hypersensitivity (%) P<0.001 Vande Casteele N, et al. Am J Gastroenterol. 2013. DOI:10.1038/ajg.2013.12. Time to IFX Discontinuation Due to LOR Patients who discontinued IFX treatment due to LOR/hypersensitivity (%) Transient ATI (n=12) Sustained ATI (n=35) Log-rank P=0.006 Years of IFX follow-up Vande Casteele N, et al. Am J Gastroenterol. 2013. DOI:10.1038/ajg.2013.12. AAA Formation Lowers Adalimumab Trough Serum Levels • 92% of the patients with a trough serum concentration measured below the threshold for detection were positive for AAA Median ADA TR (μg/mL) 8.9 (n=53) 10 8 2 0 8.8 (n=37) 6.1 (n=58) 6 4 AAA (+) AAA (-) 11.1 (n=46) 12 2.1 (n=9) 5.8 (n=30) 0.6 (n=8) Week 4 Week 12 0.1 (n=8) 0.02 (n=3) Week 24 Week 54 0.05 (n=10) Therapy Discontinuation Reprinted from Gastroenterology 137(5), Karminis K, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, 1628-1640. Copyright 2009, with permission the AGA Institute. Proposed Treatment Algorithm in the Setting of Loss of Response High titers High Clearance Switch within class Low titers Impact Clearance Drug escalation or switch High titers High Clearance Switch Low titers Impact Clearance Drug escalation or switch ADAs LOR Negative & ADAs (+) Drug Positive Subtherapeutic Drug escalation Therapeutic Change drug class (no benefit from dose escalation) Subtherapeutic & normal CRP De-escalation Ordas I et. al. Clin Gastroenterol Hepatol. 2012; 10:1079-1087. Can Antibodies to Biologic Therapies Be Overcome? • 5 patients with loss of response to infliximab, undetectable infliximab trough levels, and positive antibodies to infliximab on 2 occasions • Antimetabolite therapy added without changing dose of infliximab – Methotrexate (2); Thiopurine (3) • ATI titer decreased and trough IFX levels rose over 1-5 months • Clinical response reestablished Ben-Horin S. CGH 2013;11:444-7 Conclusion • Reactive Therapeutic Drug Monitoring effective for optimization of AntiTNF therapy in NonResponders • Most data studied with Infliximab- but likely applies to other antiTNF agents – Adalimumab – Certolizumab Pegol • Future prospective trial needed to define Proactive Drug monitoring CASE 4 • 24 year old woman with newly diagnosed Crohn’s disease of the colon, ileum and perianal skin tags with a small simple fistula – Anemic – Elevated CRP • Treated with infliximab and azathioprine • Excellent response and clinical remission • Laboratory values return to normal CASE 4 - continued • After 6 months of continuous therapy, requests to stop azathioprine • 6 weeks later, has blood per rectum, loose stools • Steroids started • Infliximab given early at higher dose • No improvement CASE 4 - continued • What happened here? • Colonoscopy performed: – complete mucosal healing – Small irritated skin tag with friability – Fistula not draining CASE 4 – continued - oops • 4 months later • Diarrhea, frank hematochezia – Anemic – CRP elevated again • C. diff negative • Therapeutic assessment – Infliximab level elevated (16 ug/ml) – No antibodies to infliximab Interpretation of Infliximab Levels and Antibodies to Infliximab in a Patient Losing Response Elevated Antibodies to Infliximab Absent Elevated Present Not elevated Absent Not elevated Present Infliximab Level Treatment recommendation Switch treatment mechanism Unclear, consider switching to another TNF-inhibitor Adjust dose, interval of infliximab Switch to another TNF-inhibitor Afif, et al. Am J Gastroenterol. 2010 ;105(5):1133-9. Switching Between TNF Inhibitors: Rheumatoid Arthritis Experience • Response to a second inhibitor is lower relative to first 1 • Response to a second inhibitor will be comparable if initial discontinuation was due to adverse events 1, 2 • Patients who do not respond to 2 TNF inhibitors are not likely to respond to a third 2 1. 2. Gomez-Reino et al. Arthritis Research & Therapy. 2006;8:R29 Solau-Gervais et al. Rheumatology. 2006;epub ahead of print. Non-Anti-TNF Mechanisms of Management for the Patient Failing anti-TNF Therapy Confirm Inflammation First Crohn’s Disease • Natalizumab • Methotrexate • Surgery Ulcerative Colitis • Cyclosporine • Tacrolimus • Surgery – Including staged approaches or diversion for induction of remission • Bowel rest • Less evidence: – Mycophenolate – Tacrolimus Don’t Forget about Clinical Trials! Leukocyte Trafficking Inhibition leukocyte Brain Bone marrow Gut a4b1 integrins a 4b 7 natalizumab natalizumab Vedolizumab, rhuMab-beta7 PF-00547659 addressins VCAM-1 MadCAM-1 endothelium Updated Utilization and Safety Results of Natalizumab in CD and MS (TOUCH, CD INFORM, TYGRIS & Pregnancy Registry Studies) • 118,100 patients have received globally (postmarketing) as of 6/30/2013 – Predominantly MS patients • PML (Progressive Multifocal Leukoencephalopathy) – Rare but serious – 410 cases reported globally as of 01-Oct2013; 23% have died – Longer duration and prior immunosuppressant use increases risk – Risk for patients treated 24-36 months similar to rates seen in clinical trials – Limited safety data beyond 4 yrs of treatment – No known treatment or prevention interventions for PML https://medinfo.elan.com (accessed 12-Dec-2011); PML Incidence according to Elan Pharmaceuticals at 04Nov-2013. Recommendations for JCV Antibody Testing • Testing prior to treatment with natalizumab • If positive, consider retesting. – If confirmed, option is treatment with natalizumab for 9-12 months • If negative, may treat with natalizumab, retest every 6 months – If converts to positive, stop therapy • The benefit and safety of a drug holiday and restarting after “resetting” the exposure has not been tested in Crohn’s disease • Vedolizumab (expected approval Q2 2014) does not have PML associated with it. CASE 4 - conclusion • • • • • JCV antibody negative TOUCH program Natalizumab initiated (300 mg IV q month) Stable remission returns Ongoing monitoring – Repeat JCV antibody assessment q6 months What happens to the patients who receive natalizumab in the current post-TNF paradigm? Chicago Experience Sakuraba et al. Inflamm Bowel Dis 2013; ;19(3):621-6. SUMMARY: Avoiding Errors in IBD • Clarify diagnosis and the presence of inflammation when making treatment adjustments • “Optimize” therapy – delivery, metabolism and pK • Rule out confounders • Don’t stay within class if the mechanism has clearly failed • Remember surgery